Abstract
The diagnosis of COVID-19 is normally based on the qualitative detection of viral nucleic acid sequences. Properties of the host response are not measured but are key in determining outcome. Although metabolic profiles are well suited to capture host state, existing metabolomics studies are either underpowered, measure only a restricted subset of metabolites (‘targeted metabolomics’), compare infected individuals against uninfected control cohorts that are not suitably matched, or do not provide a compact predictive model.
We here provide a well-powered, untargeted metabolomics assessment of 120 COVID-19 patient samples acquired at hospital admission. The study aims to predict patient’s infection severity (i.e. mild or severe) and potential outcome (i.e. discharged or deceased).
High resolution untargeted LC-MS/MS analysis was performed on patient serum using both positive and negative ionization. A subset of 20 intermediary metabolites predictive of severity or outcome were selected based on univariate statistical significance and a multiple predictor Bayesian logistic regression model. The predictors were selected for their relevant biological function and include cytosine (reflecting viral load), kynurenine (reflecting host inflammatory response), nicotinuric acid, and multiple short chain acylcarnitines (energy metabolism) among others.
Currently, this approach predicts outcome and severity with a Monte Carlo cross validated area under the ROC curve of 0.792 (SD 0.09) and 0.793 (SD 0.08), respectively. Prognostic tests based on the markers discussed in this paper could allow improvement in the planning of COVID-19 patient treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the UK BBSRC (grant BB/V003976/1) and the Novo Nordisk Foundation (grant NNF10CC1016517) for financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained to use the samples included in the study from the Health Regulatory Authority and Health and Care Research Wales (HCRW), and the North-West England Research Ethics (ref: 20/NW/0332).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- AEX-LC-MS/MS
- anion-exchange LC-MS
- AF
- atrial fibrillation
- ALT
- alanine aminotransferase
- ARDS
- acute respiratory distress syndrome
- AUC
- area under the curve
- BMI
- body mass index
- BP
- systolic blood pressure
- CI
- confidence interval
- COVID-19
- Coronavirus disease 2019
- CPAP
- continuous positive airway pressure
- CRP
- C-reactive protein
- CRS
- cytokine release storms
- CV
- coefficient of variation
- eGFR
- estimated glomerular filtration rate
- ESI
- electrospray ionization
- FC
- fold change
- FDR
- false discovery rate
- FIO2
- fraction of inspired oxygen
- GC-MS
- gas chromatography mass spectrometry
- GCS
- Glasgow coma scale
- GLM
- generalized linear models
- Hb
- haemoglobin levels
- HCT
- hematocrit
- IHD
- ischaemic heart disease
- IQA
- inter-batch quality assurance
- LC-MS
- liquid chromatography mass spectrometry
- LC-MS/MS
- liquid chromatography tandem mass spectrometry
- LFC
- log fold change
- Lymphs
- lymphocyte count
- MB-PCA
- multiblock PCA
- MSI
- metabolomics Standards Initiative
- MSML
- mass spectrometry metabolite library
- NEWS
- national early warning score
- NICE
- national institute for health and care excellence
- NMR
- nuclear magnetic resonance
- OR
- odds ratio
- PCA
- principal component analysis
- PCR
- polymerase chain reaction
- PLTs
- platelets count
- QC
- quality control
- RLUH
- royal Liverpool university hospital
- ROC
- receiver operating characteristic
- rRNA
- ribosomal RNA
- RT
- retention time
- RTPCR
- reverse transcription PCR
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- SD
- standard deviation
- SOB
- shortness of breath
- WBC
- white blood cell count
